{"name":"IntraBio","slug":"intra-bio","ticker":"Private","exchange":"Private","domain":"intrabio.com","description":"IntraBio is a private biotech company focused on developing treatments for rare neurological diseases. The company's pipeline includes several promising candidates, but specific details are limited due to its private nature. As a result, IntraBio's market position and revenue are not publicly disclosed.","hq":"Oxford, UK","founded":0,"employees":"","ceo":"Michael Bhatt, FRCP","sector":"Rare Neurological Diseases / Private Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"Private (~$200M est.)","metrics":{"revenue":7305000,"revenueGrowth":-73.4,"grossMargin":0,"rdSpend":74425000,"netIncome":-86581000,"cash":104229000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2011"},"revenueBreakdown":[],"timeline":[{"date":"2024-01-01","label":"Aqneursa first approved","drug":"Aqneursa","drugSlug":"levacetylleucine","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-12-01","label":"Aqneursa PHASE3 readout","drug":"Aqneursa","drugSlug":"levacetylleucine","type":"phase3_readout","sentiment":"neutral"},{"date":"2030-06-01","label":"Galantamine patent cliff ($null at risk)","drug":"Galantamine","type":"patent_expiry","sentiment":"negative"},{"date":"2030-06-01","label":"Galantamine patent cliff ($null at risk)","drug":"Galantamine","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Aqneursa","genericName":"LEVACETYLLEUCINE","slug":"levacetylleucine","indication":"Niemann-Pick disease type C (NPC)","status":"marketed"},{"name":"N-Acetyl-L-Leucine","genericName":"N-Acetyl-L-Leucine","slug":"n-acetyl-l-leucine","indication":"Cerebellar ataxia","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"IB1001","genericName":"IB1001","slug":"ib1001","indication":"Multiple myeloma (in development)","status":"phase_3"}]}],"pipeline":[{"name":"IB1001","genericName":"IB1001","slug":"ib1001","phase":"phase_3","mechanism":"IB1001 is an intrabone injection therapy designed to deliver therapeutic agents directly into the bone marrow microenvironment.","indications":["Multiple myeloma (in development)"],"catalyst":""},{"name":"Aqneursa","genericName":"LEVACETYLLEUCINE","slug":"levacetylleucine","phase":"marketed","mechanism":"Aqneursa works by modifying the activity of a specific enzyme involved in the breakdown of fatty substances in the body.","indications":["Niemann-Pick disease type C (NPC)"],"catalyst":""},{"name":"N-Acetyl-L-Leucine","genericName":"N-Acetyl-L-Leucine","slug":"n-acetyl-l-leucine","phase":"phase_3","mechanism":"N-Acetyl-L-Leucine enhances mitochondrial energy metabolism and reduces neuroinflammation to improve vestibular and cerebellar function.","indications":["Cerebellar ataxia","Vertigo and balance disorders","Spinocerebellar ataxia"],"catalyst":""}],"recentEvents":[{"date":"2024-02-22","type":"deal","headline":"IntraBio Raises $15M in Series A Funding","summary":"IntraBio secured $15 million in Series A funding to support the development of its rare neurological disease treatments.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxOUGRvdWotU2l1cHhvUGgycER1Y0ZQT0kxWFBoOHhlekY4ai1oV2NVVThIbVZ4ekdjaU16cWlianV2SGp3dkpLcE5IYUhsUzJJdlBEQUszRjlJZUY3UWZrSUwyVjI0SmhBRDZsd09zVDNzbHRDOVNCb3lEQ2c4OE1xaXlXYWlBcXF2blRpaTJVNGVPbkNBdFRybnRWeUJvLVRLYXktWWhxdkt0RGlmeWJUN3drTEhFekh4TmJHczNlWUFFUGxUMDQw?oc=5","date":"2026-01-21","type":"regulatory","source":"Fierce Pharma","summary":"IntraBio's Aqneursa, on a roll with EU approval, races toward another rare disease indication with phase 3 win - Fierce Pharma","headline":"IntraBio's Aqneursa, on a roll with EU approval, races toward another rare disease indication with phase 3 win","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxNWGVsQnhXbzE5WTJkUDg3UElKUHFRQ0lrSjlDTk9iLVc4SXUzSmpzSDBlaTNHdFZLMGhaZXEyUm9RUzU5R3ZyWmoxYUQ4WWhwSjVNeXBGUlJDZkJlUVY4TUxWQnFkX1pacUVZY19wME1ERFFmUFJxNWNmNi1kRmI1clM1eWhaT0daSVdfcVFLV1VoRnEwcGhfTVNXdWRJR1k?oc=5","date":"2025-06-12","type":"pipeline","source":"EY","summary":"How IntraBio's finance transformation fueled its global expansion - EY","headline":"How IntraBio's finance transformation fueled its global expansion","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-01-08","type":"regulatory","source":"CNBC","summary":"Healthy Returns: The FDA approved fewer new drugs in 2024 — but some big ones hit the market - CNBC","headline":"Healthy Returns: The FDA approved fewer new drugs in 2024 — but some big ones hit the market","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiZkFVX3lxTE9FRFRiTDB6LURRYnBOeEZRRFJYTVBaVlZxX251YXA4cDdnak9ETjN4TThkS0NfOE53cFkyTEU5MVJvQkcxU21SanBTRFEtTk9zQzIxc1Qxb0FXbDZ3Q3N1THVtc05yUQ?oc=5","date":"2024-10-10","type":"pipeline","source":"Labiotech.eu","summary":"12 biotech unicorns revolutionizing the future of healthcare - Labiotech.eu","headline":"12 biotech unicorns revolutionizing the future of healthcare","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxOaHFRRHh0dU9QZzB1dDNCRTJiVkY5WTNQUTlrWEtabE9teDR0Y000aXFwbHYzMFBCMmJpUEtPMUdtUU85UlJKM3pSOHphQjBxWlQ0dU9TNVZXYmtJbUZJZE1vV3d2d1FSaXdqd1RpdFU3bTlnNUo1WnZ4OWotRXI1eHNkWG9hTHRKZ19hQ05wWW5jcGtlZEQ5TUVGUHEzdUU4LXpXbnJtRUhVQmNaNEt4dFlNOGFnNWZWbUEtNGtfTQ?oc=5","date":"2024-09-30","type":"regulatory","source":"Fierce Pharma","summary":"After landmark rare disease approval, IntraBio ready to 'hit the ground running' with Aqneursa launch - Fierce Pharma","headline":"After landmark rare disease approval, IntraBio ready to 'hit the ground running' with Aqneursa launch","sentiment":"positive"},{"date":"2012-06-22","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"}],"patents":[{"drugName":"Galantamine","drugSlug":"galantamine","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US"}],"drugCount":3,"phaseCounts":{"phase_3":2,"marketed":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Biogen","Roche","Pfizer"],"therapeuticFocus":["Rare Neurological Diseases"],"financials":{"source":"sec_edgar+yahoo","revenue":7305000,"revenuePeriod":"2011-12-31","revenueHistory":[{"value":7305000,"period":"2011-12-31"},{"value":27419000,"period":"2010-12-31"},{"value":22936000,"period":"2009-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":74425000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-86581000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":104229000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}